09. September 2026
GBA changes its visual identity, logo and claim
Berlin, 9 September 2026
The Federal Joint Committee (GBA) is giving itself a new visual identity. The logo is being revised as well: the previous “G-BA” becomes the word mark …
G-BA Resolutions.
Clearly analysed.
The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
Current resolutions
News
All articles
Read more →
07. September 2026
Fourth JCA available: onasemnogene abeparvovec (Itvisma®) for the treatment of 5q spinal muscular atrophy (SMA)
For the active substance onasemnogene abeparvovec (Itvisma®) for the treatment of 5q spinal muscular atrophy (SMA) in patients aged 2 years and older with a biallelic mutation in the survival …
17. August 2026
New EU-HTA procedure initiated: First tissue-engineered ATMP
The medicinal product is identified as “bi-layer engineered skin composed of autologous keratinocytes and allogeneic fibroblasts embedded in an allogeneic plasma matrix”. It is indicated for the treatment of partial …
Features at a glance
Individual decision at a glance
Key data from all AMNOG decisions, summarized in a compact and structured format.
Interactive analysis
Analyze your own research questions by filtering across more than 120 parameters.
Smart search
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends and annual therapy cost tracking
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU-HTA
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export and bookmarks
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.